지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술대회자료
- 저자정보
- 발행연도
- 2014.4
- 수록면
- 403 - 410 (8page)
이용수
초록· 키워드
오류제보하기
Therapy for hepatitis C is undergoing a revolution. All-oral, interferon-free combinations of drugs are expected to cure more than 90% of infections. A huge amount of data from clinical trials are presented regularly at international conferences or released to the press, creating confusion in the viral hepatitis field. Even though new DAAs have stronger antiviral activity against HCV, there are still a lot of difficult-to-treat patients infected with HCV. Clinicians also need to be aware of drug-drug interaction as well as other adverse events with the use of most DAAs. Many unanswered questions remain, such as how to re-treat patients who failed on treatment, the potent role of interferon-free regimens, and how to best treat these special populations.
This review outlines best treatment strategies for difficult to treat HCV patients, including those that are interferon-based and interferon-free.
This review outlines best treatment strategies for difficult to treat HCV patients, including those that are interferon-based and interferon-free.
목차
HCV-infected patients who fail DAA therapies
HCV-infected patients with advanced fibrosis/cirrhosis
Elderly patients
HCV-HIV co-infected patients
HCV-infected patients associated with liver transplantation
HCV-infected patients with renal impairment or ESRD requiring hemodialysis
Reference
참고문헌 (0)
참고문헌 신청이 논문의 저자 정보
최근 본 자료
댓글(0)
0